key: cord-0955929-fqsot5yb authors: Li, Yun; Chen, Baixin; Hong, Zhuoting; Sun, Qimeng; Dai, Yanyuan; Basta, Maria; Tang, Xiangdong; Qin, Qingsong title: Insomnia symptoms during the early and late stages of the COVID-19 pandemic in China: a systematic review and meta-analysis() date: 2021-09-28 journal: Sleep Med DOI: 10.1016/j.sleep.2021.09.014 sha: e570844db1452f82e66f2c51fd3bd2f2b7349d14 doc_id: 955929 cord_uid: fqsot5yb BACKGROUND: Evidence suggests that the outbreak of the coronavirus disease 2019 (COVID-19) and the prevention/control measures for COVID-19 may cause insomnia during the acute phase of COVID-19 pandemic in China. However, it is unclear whether insomnia sustains during the later phases of the pandemic. METHODS: We searched PubMed/Medline, EMBASE, PsycINFO and China National Knowledge Infrastructure from the 27(th) December 2019 to the 2(nd) February 2021. As early stage studies on COVID-19 pandemic in China were defined as those conducted prior to April 1(st), 2020, while late stage studies were those conducted after April 1(st), 2020. RESULTS: A total of 98 studies with 193,889 participants were included. The pooled prevalence of insomnia symptoms among all populations was 39.1%; the pooled prevalence of insomnia symptoms during the early and late stages of COVID-19 in China were 37.0% (95% CI 34.1-39.9%) and 41.8% (95% CI 33.6-50.0%), respectively. Importantly, there was no significant difference regarding the prevalence of insomnia symptoms between the early and late stages of COVID-19. Meta-regression showed that healthcare workers, COVID-19 patients, patients with chronic medical conditions and patients with mental disorders had a higher prevalence of insomnia symptoms compared to the general population. This association remained significant in healthcare workers and patients with chronic medical conditions after adjusting for age, gender, areas of high or low prevalence of COVID-19 cases, anxiety and depression. CONCLUSIONS: Over one third of our sample presented insomnia symptoms during the early stage of COVID-19 pandemic in China. Interestingly, prevalence of insomnia symptoms sustained high during the late stage of the pandemic despite the control of the disease and the amelioration of its adverse effects. Our findings suggest that insomnia symptoms related to COVID-19 appear to persist of over time. For more information, visit www.prisma-statement.org. Since mid-March 2020, work and daily life gradually returned to normal among most provinces in China, and the newly confirmed cases resulted mainly from inbound cases [3] . (1) to conduct a systematic review and meta-analysis on the prevalence of insomnia symptoms during the early and late stages of the COVID-19 pandemic in China, and (2) to determine the prevalence of insomnia symptoms in specific populations during the pandemic. We conducted this review and meta-analysis according to Preferred Reporting Items for Systematic Review and Meta-analysis protocols (PRISMA-P) checklist [6] . This study was registered in the Prospective Register of Systematic Reviews (CRD well-established validated scales/questionnaires to measure sleep. In order to diminish the bias of prevalence of insomnia symptoms due to non-standardized scales/questionnaires, we did not include studies that used self-designed measures or a subsection or cluster of questions to measure sleep problems. The exclusion criteria were: 1) use of self-designed measures or a subsection or cluster of questions to report sleep problems; 2) abstracts; 3) articles that did not report insomnia data; 4) reviews or case reports. were considered as separate studies in the subsequent data extraction and analyses. If the prevalence of insomnia symptoms was provided for the total sample and subgroups simultaneously, the data of the total sample was extracted and used for analyzing the estimated pooled prevalence among the overall population, while the data of the subgroups was used for analyzing the estimated pooled prevalence in the corresponding subgroups. The "early stage" of COVID-19 pandemic in China was defined as the time In this meta-analysis, insomnia symptoms were defined based on the well-established validated scales/questionnaires that assess insomnia symptoms from the original studies. The study quality was assessed using an 11-item checklist which was recommended by the Agency for Healthcare Research and Quality (AHRQ) [7] . An item would be scored '0' if the answer was 'NO' or 'UNCLEAR'; and "1" if the answer was 'YES', then the item would be scored '1'. Article quality was assessed as follows: low quality = 0-3; moderate quality = 4-7; high quality = 8-11. The total scores and detailed AHRQ checklist for each article were provided in Supplementary The pooled prevalence and 95% confidence intervals (95% CIs) of insomnia symptoms were calculated according to the Cochrane Handbook [8] . Since the I 2 , an indicator of heterogeneity, was greater than 50% in all meta-analyses, the random J o u r n a l P r e -p r o o f effect was used for all models [8] . As the prevalence of insomnia symptoms may vary among different populations, subgroup meta-analyses were conducted to assess the A total of 395 articles and abstracts were identified in the search strategy. Among the 98 studies included with 193,889 participants, prevalence of insomnia symptoms ranged from 2.6% to 100% during the COVID-19 pandemic in China. Random-effects meta-analysis showed that the overall estimated pooled prevalence of insomnia symptoms was 39.1% (95% CI 36.2-42.0%, I 2 =99.5%, Figure 3 and (Supplementary Figure 4) . Among the 82 studies with 172,607 participants, prevalence of insomnia symptoms ranged from 2.6% to 100% during the early stage of the COVID-19 pandemic in China. Random-effects meta-analysis showed that the estimated pooled J o u r n a l P r e -p r o o f prevalence of insomnia symptoms during the early stage was 37.0% (95% CI 34.1-39.9%, I 2 =99.5%, Figure 4) . Inspection of the funnel plot indicated no significant publication bias (Supplementary Figure 5) , and sensitivity analysis confirmed that the stability of the result was not violated after omitting any particular study. Figure 4 ). In order to examine the prevalence of insomnia symptoms in specific sub-populations during the COVID-19 pandemic in China, we conducted the following subgroup analyses among the overall samples. Among the 37 studies with 155,583 subjects including the general population samples, prevalence of insomnia symptoms ranged from 2.6% to 60. Figure 6) , and sensitivity analysis confirmed that the stability of the result was not violated after omitting any particular study. Among the 48 studies with 33,021 subjects including healthcare workers, prevalence of insomnia symptoms ranged from 14.2% to 100% during the COVID-19 pandemic in China. Random-effects meta-analysis showed that the estimated pooled prevalence of insomnia symptoms was 46.4% (95% CI 40.3-52.5%, I 2 =99.5%, Figure 3 ) Random-effects meta-analysis showed that the estimated pooled prevalence of insomnia symptoms was significantly higher in front-line healthcare workers (56.7%, 95% CI 45.9-67.5%, I 2 =99.5%) compared to that in non-front-line/non-specified healthcare workers (38.0%, 95% CI 33.8-42.2%, I 2 =97.6%, between-group p<0.001, Supplementary Figure 8 ). Among the 6 studies with 1,780 COVID-19 patients, prevalence of insomnia symptoms ranged from 10.2% to 84.7% during the COVID-19 pandemic in China. Random-effects meta-analysis showed that the estimated pooled prevalence of insomnia symptoms was 48.7% (95% CI 21.6-75.8%, I 2 =99.5%, Figure 3 ). Sensitivity analysis confirmed the stability of the result was not violated after omitting any particular study. Among the 5 studies with 3,185 subjects with chronic medical conditions, 2 studies included patients with breast cancer and the 3 remaining studies focused on patients with diabetes, Parkinson's disease, and various chronic diseases, respectively. Prevalence of insomnia symptoms among patients with chronic medical conditions ranged from 26.2% to 68.9% during the COVID-19 pandemic in China. Random-effects meta-analysis showed that the estimated pooled prevalence of insomnia symptoms was 49.3% (95% CI 32.5-66.1%, I 2 =98.5%, Figure 3 ). Sensitivity analysis confirmed the stability of the result was not violated after omitting any particular study. Among the 2 studies with 320 subjects with mental disorders, the prevalence of insomnia symptoms was 53.9% and 66.0%, respectively. Random-effects meta-analysis showed that the estimated pooled prevalence of insomnia symptoms was 60.9% (95% CI 49.2-72.6%, I 2 =71.4%, Figure 3 ). In the current meta-analysis, the prevalence of insomnia symptoms among all populations is 39.1%. Our finding appears to be slightly higher compared to the prevalence of 35.7% reported in a recent meta-analysis for the pooled prevalence of insomnia symptoms in adults from 13 countries [10] . In this previous meta-analysis, subgroup analysis by country determined that the pooled prevalences of insomnia symptoms in China, Italy, France and Germany were 26.5%, 55%, 50.8% and 38.8%, respectively. The higher prevalence of insomnia symptoms in our study could be attributed to the methodological differences that we included more studies on healthcare workers (48.9% vs. 33.0%) that are known to present higher prevalence of insomnia symptoms compared to the general population due to increased workload and higher risk of being infected with COVID-19 [11] [12] [13] . Interestingly, we did not observe a significant difference in pooled prevalence of insomnia symptoms between the early and late stages, though the COVID-19 spread has been controlled in China and the daily life has returned to a relatively normal situation. These findings suggest that the effects of COVID-19 on insomnia symptoms may persist, suggesting long-term follow-up and interventions for sleep are needed. However, since the COVID-19 pandemic is still continuing in many other countries, our findings may not be generalized to these countries. Further prolongation of the COVID-19 pandemic may further worsen insomnia and insomnia-related psychological and medical issues. Thus, long-term follow-up for sleep disturbance is warranted. Risk factors for insomnia symptoms during the early and late stages of the COVID-19 pandemic may differ. During the early stage, insomnia symptoms have been reported to be mainly associated with acute psychological reactions due to the rapid spread of the disease (i.e., fear of getting SARS-CoV-2 infected) and the strict J o u r n a l P r e -p r o o f implementations for controlling the COVID-19 pandemic (i.e., quarantine, social distancing, lockdown, school and factory shut-down, limited access to hospitals, and traffic restrictions) [14, 15] , as well as poor sleep hygiene [5, 16] . During the late stage of the COVID-19 pandemic, insomnia symptoms are associated with long-term effects of the COVID-19 pandemic on economic stress [17, 18] and mental health problems [19] [20] [21] . Before the COVID-19 pandemic, the prevalence of insomnia symptoms in China was 15% in the adult general population [22] and 35.9% among older adults [23] . In the current meta-analysis, prevalence of insomnia symptoms among the general population was 26%, which is higher than the prevalence in the adult general population [22] but lower than for older adults [23] before the COVID-19 pandemic in China. A recent meta-analysis [10] showed that, similar to our study, the pooled prevalence of sleep problems in China during the COVID-19 pandemic was 26%. In a previous study conducted by our group during the COVID-19 outbreak in China, we found that worsened insomnia during COVID-19 outbreak was significantly associated with stress, anxiety and depressive symptoms and prolonged time in bed [5] . It appears that psychological symptoms and insomnia symptoms may have a bidirectional relationship during the COVID-19 pandemic, suggesting that sleep specialists should consider psychiatric comorbidities and sleep hygiene education when treating sleep problems and vice versa. Compared to a recent meta-analysis evaluating the prevalence of insomnia symptoms during the COVID-19 from 13 countries [10] , the pooled prevalence of insomnia symptoms was lower in our study (26% vs. 32%). Our findings of lower prevalence of insomnia symptoms in the general population in China during the COVID-19 pandemic is consistent with the subgroup analysis by country in this meta-analysis [10] . In this meta-analysis, the authors reported that the estimated pooled prevalence of insomnia symptoms in China is lower than in Italy, France and Germany [10] . In our study, we found a very highalmost double compared to the general population-pooled prevalence of insomnia symptoms in healthcare workers that increased during the pandemic compared to the pre-pandemic period [24] . This may be due to increased COVID-19-related stress and workload during the pandemic. Importantly, the association remained significant even after adjusting for age, gender, areas of high or low prevalence of COVID-19 cases, anxiety and depressive symptoms, suggesting that insomnia symptoms may be independent of psychological symptoms. Other factors, i.e., shift work, poor sleep environment and high-intensity work, may play a more important role in insomnia in healthcare workers during the COVID-19 pandemic. As expected, front-line healthcare workers had a higher prevalence of insomnia symptoms compared to non-front-line healthcare workers. This finding may be associated with direct contact with COVID-19 patients [25] [26] [27] . Thus, front-line healthcare workers may have a higher risk of being infected by COVID-19, more intensive work [28] , isolation from their families [11, 29] and higher levels of COVID-19-related stress, anxiety, depression [30] [31] [32] . In contrast to our study, two recent meta-analyses reported slightly lower prevalence of insomnia symptoms among healthcare workers [10, 33] [62] , longitudinal studies should also examine the long-term effects of COVID-19-related insomnia symptoms on mental health problems (i.e., post-traumatic stress disorder, obsessive compulsive disorder, depression and anxiety disorders) and cardiometabolic diseases. Our systematic review and meta-analysis has the following strengths: 1) it includes 98 studies from 81 articles with 193,889 participants; 2) careful selection of included studies that used standardized questionnaires/scales to assess insomnia symptoms; 3) is the first study to compare the prevalence of insomnia symptoms during the early and late stages of COVID-19 pandemic, and 4) is the first meta-analysis to include anxiety and depression as covariates in meta-regression analyses to examine the independent association of different populations with J o u r n a l P r e -p r o o f insomnia symptoms during the COVID-19 pandemic. However, some limitations should be acknowledged. First, the heterogeneity is high. However, findings of sensitivity analysis suggest our results are stable. Differences in the prevalence of insomnia symptoms in different populations may explain the high heterogeneity. Another possible explanation for the high heterogeneity may be associated with different sleep measures for assessing insomnia symptoms across different time frames (e.g., PSQI and AIS assess symptoms during the past month, while the ISI assesses symptoms during the past 2 weeks). However, it has been reported that there is no significant difference regarding the sensitivity and specificity of the diagnostic accuracy among the PSQI, ISI and AIS for screening insomnia [63] . Second, the number of studies that were conducted during the late stage of COVID-19 pandemic in China is relatively small, which prevents further analyses of the prevalence of insomnia symptoms in different specific sub-populations during the late stage of the COVID-19 pandemic. Over one third of our sample presented insomnia symptoms during the early stage Distribution of COVID-19 outbreaks Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV Full Text: Fighting COVID-19: China in Action All temporary treament centers were closed Insomnia and psychological reactions during the COVID-19 outbreak in China Preferred reporting items for systematic review and meta-analysis J o u r n a l P r e -p r o o f protocols (prisma-p) 2015 statement Agency for Healthcare Research and Quality (US) Cochrane Handbook for Systematic Reviews of Interventions Cochrane Handbook for Systematic Reviews of Interventions Sleep problems during the COVID-19 pandemic by population: a systematic review and meta-analysis Sleep Disturbance and Psychological Profiles of Medical Staff and Non-Medical Staff During the Early Outbreak of COVID-19 in Hubei Province COVID-19) epidemic on medical staff in different posts in China: A multicenter study Mental Health and Psychosocial Problems of Medical Health Workers during the COVID-19 Psychother Psychosom Indoor) isolation, stress and physical inactivity: vicious circles accelerated by Covid-19? A novel approach of consultation on 2019 novel coronavirus (COVID-19)-related psychological and mental problems: Structured letter therapy Stress, anxiety, depression and insomnia in adults outside Hubei province during the COVID-19 pandemic Factors Associated with Mental Health Results among Workers with Income Losses Exposed to COVID-19 in China Mental Health and Work Attitudes among People Resuming Work during the COVID-19 Pandemic: A Cross-Sectional Study in China Relationship between eHealth literacy and psychological status during COVID-19 pandemic: A survey of Chinese residents Prevalence of sleep disturbances during COVID-19 outbreak in an urban Chinese population: a cross-sectional study Psychological reactions and insomnia in adults with mental health disorders during the COVID-19 outbreak The prevalence of insomnia in the general population in China: A meta-analysis Prevalence of Sleep Disturbances and Sleep Quality in Older Chinese Adults: A Comprehensive Meta-Analysis Prevalence of sleep disturbances in Chinese healthcare professionals: a systematic review and meta-analysis The mental health of frontline and non-frontline medical workers during the coronavirus disease 2019 (COVID-19) outbreak in China: A case-control study Nurses endured high risks of psychological problems under the epidemic of COVID-19 in a longitudinal study in Wuhan China Factors Associated With Mental Health Outcomes Among Health Care Workers Exposed to Coronavirus Disease The prevalence and risk factors of psychological disturbances of frontline medical staff in china under the COVID-19 epidemic: Workload should be concerned COVID-19 on the families of first-line rescuers Anxiety in Chinese pediatric medical staff during the outbreak of Coronavirus Disease 2019: a cross-sectional study Nurses' Sleep Quality of "Fangcang" Hospital in China during the COVID-19 Pandemic Sleep quality and mood symptoms in conscripted frontline nurse in Wuhan, China during COVID-19 outbreak: A cross-sectional study Prevalence of depression, anxiety, and insomnia among healthcare workers during the COVID-19 pandemic: A systematic review and meta-analysis Factors related to mental health of inpatients with COVID-19 in Wuhan, China. Brain Behav Immun A psychological investigation of coronavirus disease 2019 (COVID-19) patients in mobile cabin hospitals in Wuhan Life with Parkinson's Disease During the COVID-19 Pandemic: The Pressure Is "OFF Impact of home confinement during COVID-19 pandemic on sleep parameters in Parkinson's disease COVID-19 Pandemic Stressors and Psychological Symptoms in Breast Cancer Patients Sleep in Parkinson's disease The Epidemiology of Sleep and Diabetes Exercise, sleep and cancer-related fatigue: Are they related? Patient-reported Outcomes of Patients With Breast Cancer During the COVID-19 Outbreak in the Epicenter of China: A Cross-sectional Survey Study The Psychological Pressures of Breast Cancer Patients During the COVID-19 Outbreak in China -A Comparison With Frontline Female Nurses. Front Psychiatry Investigation on sleep and mental health of patients with Parkinson's disease during the Coronavirus disease 2019 pandemic Wang Lihua LW. Study on glycemic profiles and emotional scales in diabetic patients after the outbreak of COVID-19 SARS-CoV-2 Transmission in Patients with Cancer at a Tertiary Care Hospital in Wuhan, China Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Strategies used by psychotic individuals to cope with life stress and symptoms of illness: A systematic review Coping strategies and social support in old age psychosis Stress and psychosis: Towards the development of new models of investigation Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry Mental Health Response to the COVID-19 Outbreak in China Association of insomnia disorder with sociodemographic factors and poor mental health in COVID-19 inpatients in China Psychological distress and sleep quality of COVID-19 patients in Wuhan, a lockdown city as the epicenter of COVID-19 Prevalence and Demographic Correlates of Poor Sleep Quality Among Frontline Health Professionals in Liaoning Province, China During the COVID-19 Outbreak. Front psychiatry Sleep disturbances among Chinese residents during the Coronavirus Disease 2019 outbreak and associated factors Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China The psychological status of people affected by the COVID-19 outbreak in China Coping with COVID-19: Exposure to COVID-19 and Negative Impact on Livelihood Predict Elevated Mental Health Problems in Chinese Adults Epidemiologic Study of Sleep Disturbances and Psychiatric Disorders: An Opportunity for Prevention? Sleep Disturbances as an Evidence-Based Suicide Risk Factor Sleep and Cardio-Metabolic Disease A meta-analysis of diagnostic accuracy of three screening tools for insomnia This study was supported by National Natural Science Foundation of China